Barbro Eriksson

The impact of re-characterizing metastatic pancreatic neuroendocrine tumors: A prospective study

Mollazadegan, Kazhan; Botling, Johan; Skogseid, Britt; Eriksson, Barbro et al.

Part of Journal of neuroendocrinology, 2025

• DOI for The impact of re-characterizing metastatic pancreatic neuroendocrine tumors: A prospective study
• Download full text (pdf) of The impact of re-characterizing metastatic pancreatic neuroendocrine tumors: A prospective study

The evolutionary history of metastatic pancreatic neuroendocrine tumours reveals a therapy driven route to high-grade transformation

Backman, Samuel; Botling, Johan; Nord, Helena; Ghosal, Suman et al.

Part of Journal of Pathology, p. 357-370, 2024

• DOI for The evolutionary history of metastatic pancreatic neuroendocrine tumours reveals a therapy driven route to high-grade transformation
• Download full text (pdf) of The evolutionary history of metastatic pancreatic neuroendocrine tumours reveals a therapy driven route to high-grade transformation

Improved Localization of Insulinomas Using ⁶⁸Ga-NODAGA-Exendin-4 PET/CT

Boss, Marti; Eriksson, Olof; Mikkola, Kirsi; Eek, Annemarie et al.

Part of Journal of Nuclear Medicine, p. 1959-1964, 2024

• DOI for Improved Localization of Insulinomas Using ⁶⁸Ga-NODAGA-Exendin-4 PET/CT
• Download full text (pdf) of Improved Localization of Insulinomas Using ⁶⁸Ga-NODAGA-Exendin-4 PET/CT

Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors

Mollazadegan, Kazhan; Skogseid, Britt; Botling, Johan; Åkerström, Tobias et al.

Part of Endocrine Connections, 2022

• DOI for Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors
• Download full text (pdf) of Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors

177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy: Analysis of Outcome, Safety and Their Determinants

Fröss-Baron, Katarzyna; Garske, Ulrike; Welin, Staffan; Granberg, Dan et al.

Part of Neuroendocrinology, p. 330-343, 2021

• DOI for 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy: Analysis of Outcome, Safety and Their Determinants
• Download full text (pdf) of 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy: Analysis of Outcome, Safety and Their Determinants

The impact of re-characterizing metastatic pancreatic neuroendocrine tumors: A prospective study

Mollazadegan, Kazhan; Botling, Johan; Skogseid, Britt; Eriksson, Barbro et al.

Part of Journal of neuroendocrinology, 2025

• DOI for The impact of re-characterizing metastatic pancreatic neuroendocrine tumors: A prospective study
• Download full text (pdf) of The impact of re-characterizing metastatic pancreatic neuroendocrine tumors: A prospective study

The evolutionary history of metastatic pancreatic neuroendocrine tumours reveals a therapy driven route to high-grade transformation

Backman, Samuel; Botling, Johan; Nord, Helena; Ghosal, Suman et al.

Part of Journal of Pathology, p. 357-370, 2024

• DOI for The evolutionary history of metastatic pancreatic neuroendocrine tumours reveals a therapy driven route to high-grade transformation
• Download full text (pdf) of The evolutionary history of metastatic pancreatic neuroendocrine tumours reveals a therapy driven route to high-grade transformation

Improved Localization of Insulinomas Using ⁶⁸Ga-NODAGA-Exendin-4 PET/CT

Boss, Marti; Eriksson, Olof; Mikkola, Kirsi; Eek, Annemarie et al.

Part of Journal of Nuclear Medicine, p. 1959-1964, 2024

• DOI for Improved Localization of Insulinomas Using ⁶⁸Ga-NODAGA-Exendin-4 PET/CT
• Download full text (pdf) of Improved Localization of Insulinomas Using ⁶⁸Ga-NODAGA-Exendin-4 PET/CT

Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors

Mollazadegan, Kazhan; Skogseid, Britt; Botling, Johan; Åkerström, Tobias et al.

Part of Endocrine Connections, 2022

• DOI for Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors
• Download full text (pdf) of Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors

177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy: Analysis of Outcome, Safety and Their Determinants

Fröss-Baron, Katarzyna; Garske, Ulrike; Welin, Staffan; Granberg, Dan et al.

Part of Neuroendocrinology, p. 330-343, 2021

• DOI for 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy: Analysis of Outcome, Safety and Their Determinants
• Download full text (pdf) of 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy: Analysis of Outcome, Safety and Their Determinants

High-grade progression confers poor survival in pancreatic neuroendocrine tumors

Botling, Johan; Lamarca, Angela; Bajic, Duska; Norlén, Olov et al.

Part of Neuroendocrinology, p. 891-898, 2020

• DOI for High-grade progression confers poor survival in pancreatic neuroendocrine tumors

Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Garske, Ulrike; Sandström, Mattias; Fröss-Baron, Katarzyna; Lundin, Lars et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, p. 970-988, 2018

• DOI for Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity
• Download full text (pdf) of Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Parametric Net Influx Rate Images of ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE: Quantitative Accuracy and Improved Image Contrast

Ilan, Ezgi; Sandström, Mattias; Velikyan, Irina; Sundin, Anders et al.

Part of Journal of Nuclear Medicine, p. 744-749, 2017

• DOI for Parametric Net Influx Rate Images of ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE: Quantitative Accuracy and Improved Image Contrast

Neuroendocrine tumors with syndromic vasoactive intestinal polypeptide hypersecretion: a retrospective study

Antonodimitrakis, Pantelis Clewemar; Olofsson, Helena; Grimelius, Lars; Sundin, Anders et al.

Part of International Journal of Endocrine Oncology, p. 9-22, 2017

• DOI for Neuroendocrine tumors with syndromic vasoactive intestinal polypeptide hypersecretion: a retrospective study

Multiple and Secondary Hormone Secretion in Patients With Metastatic Pancreatic Neuroendocrine Tumors

Crona, Joakim; Norlén, Olov; Antonodimitrakis, Pantelis; Welin, Staffan et al.

Part of Pancreas, p. 441-441, 2017

• DOI for Multiple and Secondary Hormone Secretion in Patients With Metastatic Pancreatic Neuroendocrine Tumors

Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing

Backman, Samuel; Norlén, Olov; Eriksson, Barbro; Skogseid, Britt et al.

Part of Anticancer Research, p. 705-712, 2017

• DOI for Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing

Gender-related differences in absorbed dose to risk organs in patients receiving Lu-177-Octreotate therapy

Sandström, Mattias; Ilan, Ezgi; Fröss-Baron, Katarzyna; Garske, Ulrike et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2017

Species differences in pancreatic binding of DO3A-VS-Cys40-Exendin4

Eriksson, Olof; Rosenström, Ulrika; Selvaraju, Ram Kumar; Eriksson, Barbro et al.

Part of Acta Diabetologica, p. 1039-1045, 2017

• DOI for Species differences in pancreatic binding of DO3A-VS-Cys40-Exendin4
• Download full text (pdf) of Species differences in pancreatic binding of DO3A-VS-Cys40-Exendin4

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents

Pavel, Marianne; Valle, Juan W.; Eriksson, Barbro; Rinke, Anja et al.

Part of Neuroendocrinology, p. 266-280, 2017

• DOI for ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging.

Sundin, Anders; Arnold, Rudolf; Baudin, Eric; Cwikla, Jaroslaw B et al.

Part of Neuroendocrinology, p. 212-244, 2017

• DOI for ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging.

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy

Garcia-Carbonero, Rocio; Rinke, Anja; Valle, Juan W.; Fazio, Nicola et al.

Part of Neuroendocrinology, p. 281-294, 2017

• DOI for ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy

Whole-body MRI including diffusion-weighted MRI compared with 5-HTP PET/CT in the detection of neuroendocrine tumors

Carlbom, Lina; Caballero-Corbalán, José; Granberg, Dan; Sörensen, Jens et al.

Part of Upsala Journal of Medical Sciences, p. 43-50, 2017

• DOI for Whole-body MRI including diffusion-weighted MRI compared with 5-HTP PET/CT in the detection of neuroendocrine tumors
• Download full text (pdf) of Whole-body MRI including diffusion-weighted MRI compared with 5-HTP PET/CT in the detection of neuroendocrine tumors

miR-196a Is Specifically Regulated in FDG-PET Positive and Negative Small Intestinal Neuroendocrine Tumor Patients at Late Stage of Disease

Giandomenico, V; Li, Su-Chen; Lind, Thomas; Boccherini, M. et al.

Part of Neuroendocrinology, p. 115-115, 2016

Multiple and Secondary Hormone Secretion in Patients With Metastatic Pancreatic Neuroendocrine Tumours

Crona, Joakim; Norlén, Olov; Antonodimitrakis, Pantelis; Welin, Staffan et al.

Part of Journal of Clinical Endocrinology and Metabolism, p. 445-452, 2016

• DOI for Multiple and Secondary Hormone Secretion in Patients With Metastatic Pancreatic Neuroendocrine Tumours

ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors

Falconi, M.; Eriksson, Barbro; Kaltsas, G.; Bartsch, D. K. et al.

Part of Neuroendocrinology, p. 153-171, 2016

• DOI for ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors

Streptozocin and 5-FU for the treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity

Antonodimitrakis, Pantelis; Sundin, Anders; Wassberg, Cecilia; Granberg, Dan et al.

Part of Neuroendocrinology, p. 345-353, 2016

• DOI for Streptozocin and 5-FU for the treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

Wolin, Edward M.; Jarzab, Barbara; Eriksson, Barbro; Walter, Thomas et al.

Part of Drug Design, Development and Therapy, p. 5075-5086, 2015

• DOI for Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues
• Download full text (pdf) of Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using ¹⁷⁷Lu-DOTATATE

Ilan, Ezgi; Sandström, Mattias; Wassberg, Cecilia; Sundin, Anders et al.

Part of Journal of Nuclear Medicine, p. 177-182, 2015

• DOI for Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using ¹⁷⁷Lu-DOTATATE

Dosimetry of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 in rodents, pigs, non-human primates and human -: repeated scanning in human is possible.

Selvaraju, Ram Kumar; Bulenga, Thomas N; Espes, Daniel; Lubberink, Mark et al.

Part of American journal of nuclear medicine and molecular imaging, p. 259-69, 2015

Dosimetry of [Ga-68]Ga-DO3A-VS-Cys(40)-Exendin-4 in rodents, pigs, non-human primates and human

Velikyan, Irina; Selvaraju, Ram Kumar; Bulenga, Thomas; Espes, Daniel et al.

Part of Journal of labelled compounds & radiopharmaceuticals, 2015

A Multicenter, Randomized, Blinded, Phase 3 Study of Pasireotide LAR vs Octreotide LAR in Patients with Metastatic Neuroendocrine Tumors (NET) with Disease-Related Symptoms Inadequately Controlled by Somatostatin Analogs

Wolin, Edward M.; Jarzab, Barbara; Eriksson, Barbro; Walter, Thomas et al.

Part of Pancreas, p. 508-508, 2014

Favourable outcome after 177Lu-DOTA-octreotate therapy of patients with neuroendocrine of the rectum -an update

Garske-Roman, Ulrike E.; Sandström, Mattias; Johansson, Silvia; Fröss-Baron, Katarzyna et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2014

Pre-clinical evaluation of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 for imaging of insulinoma

Selvaraju, Ram Kumar; Velikyan, Irina; Asplund, Veronika; Johansson, Lars et al.

Part of Nuclear Medicine and Biology, p. 471-476, 2014

• DOI for Pre-clinical evaluation of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 for imaging of insulinoma

Secondary Hormonal Syndromes in Patients with Sporadic Neuroendocrine Tumors

Crona, Joakim; Eriksson, Barbro; Welin, Staffan

Part of Neuroendocrinology, p. 240-240, 2014

Quantitative Imaging of Serotonergic Biosynthesis and Degradation in the Endocrine Pancreas

Eriksson, Olof; Selvaraju, Ram K; Johansson, Lars; Eriksson, Jan W et al.

Part of Journal of Nuclear Medicine, p. 460-465, 2014

• DOI for Quantitative Imaging of Serotonergic Biosynthesis and Degradation in the Endocrine Pancreas

The Positron Emission Tomography ligand [11C]5-Hydroxy-Tryptophan can be used as a surrogate marker for the human endocrine pancreas

Eriksson, Olof; Espes, Daniel; Selvaraju, Ram K; Jansson, Emma et al.

Part of Diabetes, p. 3428-3437, 2014

• DOI for The Positron Emission Tomography ligand [11C]5-Hydroxy-Tryptophan can be used as a surrogate marker for the human endocrine pancreas

Detection of Metastatic Insulinoma by Positron Emission Tomography with [(68)Ga]Exendin-4 -: a case report

Eriksson, Olof; Velikyan, Irina; Selvaraju, Ram K; Kandeel, Fouad et al.

Part of Journal of Clinical Endocrinology and Metabolism, p. 1519-1524, 2014

• DOI for Detection of Metastatic Insulinoma by Positron Emission Tomography with [(68)Ga]Exendin-4 -: a case report

Quantitative and Qualitative Intrapatient Comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: Net Uptake Rate for Accurate Quantification.

Velikyan, Irina; Sundin, Anders; Sörensen, Jens; Lubberink, Mark et al.

Part of Journal of Nuclear Medicine, p. 204-10, 2014

• DOI for Quantitative and Qualitative Intrapatient Comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: Net Uptake Rate for Accurate Quantification.

Streptozocin and 5-fluorouracil treatment of pancreatic neuroendocrine tumors: efficacy, toxicity and prognostic factors

Eriksson, Barbro; Sundin, Anders; Wassberg, Cecilia; Skogseid, Britt et al.

Part of Wiener Klinische Wochenschrift, 2014

Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment

Sandström, Mattias; Garske-Román, Ulrike; Granberg, Dan; Johansson, Silvia et al.

Part of Journal of Nuclear Medicine, p. 33-41, 2013

• DOI for Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment

Ga-68-labelling of Exendin-4, preclinical evaluation of the resultant tracer for the imaging and quantification of insulinomas, and case patient examination

Velikyan, Irina; Selvaraju, K. Ram; Sörensen, Jens; Kandeel, Fouad et al.

Part of Journal of labelled compounds & radiopharmaceuticals, 2013

Effect of Temozolomide in Patients with Metastatic Bronchial Carcinoids

Crona, Joakim; Fanola, Irina; Lindholm, Daniel P.; Antonodimitrakis, Pantelis et al.

Part of Neuroendocrinology, p. 151-155, 2013

• DOI for Effect of Temozolomide in Patients with Metastatic Bronchial Carcinoids

Improving the Diagnosis and Management of Neuroendocrine Tumors: Utilizing New Advances in Biomarker and Molecular Imaging Science

Giandomenico, Valeria; Modlin, Irvin M.; Pontén, Fredrik; Nilsson, Mats et al.

Part of Neuroendocrinology, p. 16-30, 2013

• DOI for Improving the Diagnosis and Management of Neuroendocrine Tumors: Utilizing New Advances in Biomarker and Molecular Imaging Science

Comparison of radiation dosimetry of [Ga-68]Ga-DOTA-TOC and [Ga-68]Ga-DOTA-TATE in patients affected by neuroendocrine tumours

Velikyan, Irina; Sandström, Mattias; Garske, Ulrike; Sörensen, Jens et al.

Part of Journal of labelled compounds & radiopharmaceuticals, 2013

Comparative Biodistribution and Radiation Dosimetry of Ga-68-DOTATOC and Ga-68-DOTATATE in Patients with Neuroendocrine Tumors

Sandström, Mattias; Velikyan, Irina; Garske-Roman, Ulrike; Sörensen, Jens et al.

Part of Journal of Nuclear Medicine, p. 1755-1759, 2013

• DOI for Comparative Biodistribution and Radiation Dosimetry of Ga-68-DOTATOC and Ga-68-DOTATATE in Patients with Neuroendocrine Tumors

Lessons on Tumour Response: Imaging during Therapy with Lu-177-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma

Garske, Ulrike; Sandström, Mattias; Johansson, Silvia; Granberg, Dan et al.

Part of Theranostics, p. 459-471, 2012

• DOI for Lessons on Tumour Response: Imaging during Therapy with Lu-177-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma

Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma

Lindholm, Daniel P; Eriksson, Barbro; Granberg, Dan

Part of Medical Oncology, p. 301-303, 2012

• DOI for Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma

ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors

Falconi, Massimo; Bartsch, Detlef Klaus; Eriksson, Barbro; Klöppel, Günter et al.

Part of Neuroendocrinology, p. 120-134, 2012

• DOI for ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors

PET-Guided Surgery: High Correlation between Positron Emission Tomography with ¹¹C-5-Hydroxytryptophane (5-HTP) and Surgical Findings in Abdominal Neuroendocrine Tumours

Örlefors, Håkan; Sundin, Anders; Eriksson, Barbro; Skogseid, Britt et al.

Part of Cancers, p. 100-112, 2012

• DOI for PET-Guided Surgery: High Correlation between Positron Emission Tomography with ¹¹C-5-Hydroxytryptophane (5-HTP) and Surgical Findings in Abdominal Neuroendocrine Tumours

Minor changes in effective half-life during fractionated ¹⁷⁷Lu-Octreotate therapy

Garske, Ulrike; Sandström, Mattias; Johansson, Silvia; Sundin, Anders et al.

Part of Acta Oncologica, p. 86-96, 2011

• DOI for Minor changes in effective half-life during fractionated ¹⁷⁷Lu-Octreotate therapy

ENETS Consensus Guidelines for the Management of Peritoneal Carcinomatosis from Neuroendocrine Tumors

Kianmanesh, Reza; Ruszniewski, Philippe; Rindi, Guido; Kwekkeboom, Dik et al.

Part of Neuroendocrinology, p. 333-340, 2010

• DOI for ENETS Consensus Guidelines for the Management of Peritoneal Carcinomatosis from Neuroendocrine Tumors

In vivo binding of [⁶⁸Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours — impact of peptide mass

Velikyan, Irina; Sundin, Anders; Eriksson, Barbro; Lundqvist, Hans et al.

Part of Nuclear Medicine and Biology, p. 265-275, 2010

• DOI for In vivo binding of [⁶⁸Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours — impact of peptide mass

Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec®)

Kindmark, Henrik; Janson, Eva Tiensuu; Gustavsson, Bengt; Eriksson, Camilla et al.

Part of Acta Oncologica, p. 100-101, 2010

• DOI for Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec®)

Imaging biomarkers for diagnosis and quantification with positron emission tomography: assistance to therapy

Velikyan, Irina; Sundin, Anders; Eriksson, Barbro; Lundqvist, Hans et al.

Part of Nuclear Medicine and Biology, p. 724-724, 2010

• DOI for Imaging biomarkers for diagnosis and quantification with positron emission tomography: assistance to therapy

Chromogranin A is a Sensitive Marker for Detection of Recurrence in Neuroendocrine Tumors

Janson, Eva Tiensuu; Welin, Staffan; Eriksson, Barbro; Stridsberg, Mats

Part of Neuroendocrinology, p. 63-63, 2010

• DOI for Chromogranin A is a Sensitive Marker for Detection of Recurrence in Neuroendocrine Tumors

Non-hybridisation saturable mechanisms play a role in the uptake of 68Ga-labelled LNA-DNA mixmer antisense oligonucleotides in rats

Lendvai, Gabor; Monazzam, Azita; Velikyan, Irina; Eriksson, Barbro et al.

Part of Oligonucleotides, p. 223-231, 2009

• DOI for Non-hybridisation saturable mechanisms play a role in the uptake of 68Ga-labelled LNA-DNA mixmer antisense oligonucleotides in rats

A patient with nonfunctional pancreatic neuroendocrine tumor and incidental metachronous colon carcinoma detected by positron emission tomography: Case report

Demirkan, Binnaz; Unek, Ilkay Tugba; Eriksson, Barbro; Akarsu, Mesut et al.

Part of Turkish Journal of Gastroenterology, p. 214-219, 2009

• DOI for A patient with nonfunctional pancreatic neuroendocrine tumor and incidental metachronous colon carcinoma detected by positron emission tomography: Case report

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological Examinations

Sundin, Anders; Vullierme, Marie-Pierre; Kaltsas, Gregory; Plöckinger, Ursula et al.

Part of Neuroendocrinology, p. 167-183, 2009

• DOI for ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological Examinations

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: pre- and perioperative therapy in patients with neuroendocrine tumors

Åkerström, Göran; Falconi, Massimo; Kianmanesh, Reza; Ruszniewski, Philippe et al.

Part of Neuroendocrinology, p. 203-208, 2009

• DOI for ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: pre- and perioperative therapy in patients with neuroendocrine tumors

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy

Öberg, Kjell; Ferone, Diego; Kaltsas, Gregory; Knigge, Ulrich-Peter et al.

Part of Neuroendocrinology, p. 209-213, 2009

• DOI for ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Chemotherapy in Patients with Neuroendocrine Tumors

Eriksson, Barbro; Annibale, Bruno; Bajetta, Emilio; Mitry, Emmanuel et al.

Part of Neuroendocrinology, p. 214-219, 2009

• DOI for ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Chemotherapy in Patients with Neuroendocrine Tumors

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification

Klöppel, Günter; Couvelard, Anne; Perren, Aurel; Komminoth, Paul et al.

Part of Neuroendocrinology, p. 162-166, 2009

• DOI for ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification

Elevated Plasma Chromogranin A is the First Indication of Recurrence in Radically Operated Midgut Carcinoid Tumours

Welin, Staffan; Stridsberg, Mats; Cunningham, Janet; Granberg, Dan et al.

Part of Neuroendocrinology, p. 302-307, 2009

• DOI for Elevated Plasma Chromogranin A is the First Indication of Recurrence in Radically Operated Midgut Carcinoid Tumours

Selective internal radiation therapy in patients with carcinoid liver metastases

Granberg, Dan; Garske, Ulrike; Welin, Staffan; Kindmark, Henrik et al.

Part of Acta Oncologica, p. 1169-1171, 2008

• DOI for Selective internal radiation therapy in patients with carcinoid liver metastases

Consensus guidelines for the management of patients with digestive neuroendocrine tumors: well-differentiated jejunal-ileal tumor/carcinoma

Eriksson, Barbro; Klöppel, Günter; Krenning, Eric; Ahlman, Håkan et al.

Part of Neuroendocrinology, p. 8-19, 2008

• DOI for Consensus guidelines for the management of patients with digestive neuroendocrine tumors: well-differentiated jejunal-ileal tumor/carcinoma

Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution

Ekeblad, Sara; Skogseid, Britt; Dunder, Kristina; Oberg, Kjell et al.

Part of Clinical Cancer Research, p. 7798-7803, 2008

• DOI for Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution

Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors

Eriksson, John; Stålberg, Peter; Nilsson, Anders; Krause, Johan et al.

Part of World Journal of Surgery, p. 930-938, 2008

• DOI for Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors

Biodistribution of Ga-68-labeled LNA-DNA mixmer antisense oligonucleotides for rat Chromogranin-A

Lendvai, Gabor; Velikyan, Irina; Estrada, Sergio; Eriksson, Barbro et al.

Part of Oligonucleotides, p. 33-49, 2008

• DOI for Biodistribution of Ga-68-labeled LNA-DNA mixmer antisense oligonucleotides for rat Chromogranin-A

Measurements of secretogranins II, III, V and proconvertases 1/3 and 2 in plasma from patients with neuroendocrine tumours

Stridsberg, Mats; Eriksson, Barbro; Janson, Eva Tiensuu

Part of Regulatory Peptides, p. 95-98, 2008

• DOI for Measurements of secretogranins II, III, V and proconvertases 1/3 and 2 in plasma from patients with neuroendocrine tumours

Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years

Kindmark, Henrik; Sundin, Anders; Granberg, Dan; Dunder, Kristina et al.

Part of Medical Oncology, p. 330-337, 2007

• DOI for Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

Ekeblad, Sara; Sundin, Anders; Janson, Eva Tiensuu; Welin, Staffan et al.

Part of Clinical Cancer Research, p. 2986-2991, 2007

• DOI for Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

Liver embolization with trisacryl gelatin microspheres (embosphere) in patients with neuroendocrine tumors

Granberg, Dan; Eriksson, Lars-Gunnar; Welin, Staffan; Kindmark, Henrik et al.

Part of Acta Radiologica, p. 180-185, 2007

• DOI for Liver embolization with trisacryl gelatin microspheres (embosphere) in patients with neuroendocrine tumors

Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas

Fjällskog, Marie-Louise; Hessman, Ola; Eriksson, Barbro; Janson, Eva Tiensuu

Part of Acta Oncologica, p. 741-746, 2007

• DOI for Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas

Co-expression of ghrelin and its receptor in pancreatic endocrine tumours

Ekeblad, Sara; Lejonklou, Margareta Halin; Grimfjärd, Per; Johansson, Térèse et al.

Part of Clinical Endocrinology, p. 115-122, 2007

• DOI for Co-expression of ghrelin and its receptor in pancreatic endocrine tumours

Measurements of chromogranin B can serve as a complement to chromogranin A

Stridsberg, Mats; Eriksson, Barbro; Fellström, Bengt; Kristiansson, Gudjon et al.

Part of Regulatory Peptides, p. 80-83, 2007

• DOI for Measurements of chromogranin B can serve as a complement to chromogranin A

Lungcarcinoider: inte så benigna som man trott

Granberg, Dan; Eriksson, Barbro; Janson, Eva Tiensuu; Öberg, Kjell et al.

Part of Läkartidningen, p. 2382-2384, 2006

Well-differentiated pancreatic tumor/carcinoma: insulinoma

de Herder, Wouter W.; Niederle, Bruno; Scoazec, Jean-Yves; Pauwels, Stanislas et al.

Part of Neuroendocrinology, p. 183-188, 2006

• DOI for Well-differentiated pancreatic tumor/carcinoma: insulinoma

Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography

Örlefors, Håkan; Sundin, Anders; Lu, L.; Öberg, Kjell et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, p. 60-65, 2006

• DOI for Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography

Bilateral adrenalectomy for ectopic Cushing syndrome -: discussions on technique and indication

Hellman, Per; Linder, F; Hennings, Joakim; Hessman, Ola et al.

Part of World J Surg, p. 909-916, 2006

Whole-Body 11C-5-Hydroxytryptophan Positron Emission Tomography as a Universal Imaging Technique for Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and Computed Tomography

Örlefors, Håkan; Sundin, Anders; Garske, Ulrike; Juhlin, Claes et al.

Part of Journal of Clinical Endocrinology and Metabolism, p. 3392-3400, 2005

• DOI for Whole-Body 11C-5-Hydroxytryptophan Positron Emission Tomography as a Universal Imaging Technique for Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and Computed Tomography

Developments in PET for the detection of endocrine tumours

Eriksson, Barbro; Örlefors, Håkan; Öberg, Kjell; Sundin, Anders et al.

Part of Baillière's Best Practice & Research. Clinical Endocrinology & Metabolism, p. 311-324, 2005

• DOI for Developments in PET for the detection of endocrine tumours

A panel of 13 region-specific radioimmunoassays for measurements of human chromogranin B.

Stridsberg, Mats; Eriksson, Barbro; Oberg, Kjell; Tiensuu Janson, Eva

Part of Regul Pept, p. 193-9, 2005

Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours

Öberg, Kjell; Eriksson, Barbro

Part of Best Practice & Research Clinical Endocrinology & Metabolism, p. 265-276, 2005

• DOI for Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours

PET in the diagnosis of neuroendocrine tumors

Sundin, Anders; Eriksson, Barbro; Bergström, Mats; Långström, Bengt et al.

Part of Annals of the New York Academy of Sciences, p. 246-257, 2004

• DOI for PET in the diagnosis of neuroendocrine tumors

High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours

Welin, Staffan; Janson, Eva Tiensuu; Sundin, Anders; Stridsberg, Mats et al.

Part of European Journal of Endocrinology, p. 107-112, 2004

• DOI for High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours

Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide

Ruszniewski, Philippe; Ish-Shalom, Sofia; Wymenga, Machteld; O'Toole, Dermot et al.

Part of Neuroendocrinology, p. 244-251, 2004

• DOI for Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide

A panel of 11 region-specific radioimmunoassays for measurements of human chromogranin A.

Stridsberg, Mats; Eriksson, Barbro; Oberg, Kjell; Tiensuu Janson, Eva

Part of Regul Pept, p. 219-27, 2004

Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types.

Oberg, Kjell; Astrup, Lone; Eriksson, Barbro; Falkmer, Sture E et al.

Part of Acta Oncol, p. 626-36, 2004

Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview.

Öberg, Kjell; Astrup, Lone; Eriksson, Barbro; Falkmer, Sture E et al.

Part of Acta Oncol, p. 617-25, 2004

Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors

Fjällskog, Marie-Louise; Ludvigsen, Eva; Stridsberg, Mats; Öberg, Kjell et al.

Part of Medical Oncology, p. 59-67, 2003

• DOI for Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors

Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue andintratumoral vessels in malignant endocrine pancreatic tumors.

Fjallskog, ML; Ludvigsen, E; Stridsberg, M; Oberg, K et al.

Part of Med Oncol, p. 59, 2003

In Situ RNA-RNA Hybridization of Phospholipase C β3 Shows Lack of Expression in Neuroendocrine Tumours

Stålberg, Peter; Granberg, Dan; Carling, Tobias; Wilander, Erik et al.

Part of Anticancer Research, p. 2227-2232, 2003

The role of PET in localization of neuroendocrine and adrenocortical tumors

Eriksson, Barbro; Bergström, Mats; Sundin, Anders; Juhlin, Claes et al.

Part of Annals of the New York Academy of Sciences, p. 159-169, 2002

• DOI for The role of PET in localization of neuroendocrine and adrenocortical tumors

Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs.

Fjällskog, M L; Sundin, A; Westlin, J E; Öberg, K et al.

Part of Med Oncol, p. 35-42, 2002

Experience in treatment of metastatic pulmonary carcinoid tumors

Granberg, Dan; Eriksson, Barbro; Wilander, Erik; Grimfjärd, Per et al.

Part of Annals of Oncology, p. 1383-1391, 2001

Levels of angiogenic peptides in sera from patients with carcinoid tumoursduring alpha-interferon treatment.

Nilsson, A; Tiensuu Janson, E; Eriksson, B; Larsson, A

Part of Anticancer Res., p. 4087, 2001

Treatment with Cisplatin and Etoposide in Patients with Neuroendocrine Tumors

Fjällskog, Marie-Louise; Granberg, Dan; Welin, Staffan; Eriksson, Christoffer et al.

Part of Cancer, p. 1101-1107, 2001

Use of PET in neuroendocrine tumors: In vivo applications and in vitro studies

Eriksson, Barbro; Bergström, Mats; Örlefors, Håkan; Sundin, Anders et al.

Part of The Quarterly journal of nuclear medicine, p. 68-76, 2000

Demonstration of [11C] 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography.

Sundin, A; Eriksson, B; Bergström, M; Bjurling, P et al.

Part of Nucl Med Biol, p. 33-41, 2000

Transmembrane protein tyrosine phosphatase IA-2 (ICA512) is expressed inhuman midgut carcinoids but is not detectable in normal enterochromaffincells.

Cunningham, JL; Lopez-Egido, JR; Tiensuu Janson, E; Eriksson, B et al.

Part of J Endocrinol, p. 315, 2000

PET with [¹¹C]-Metomidate for the Visualization of Adrenocortical Tumors and Discrimination from Other Lesions

Bergström, Mats; Sörensen, Jens; Khan, Tanweera Shaheena; Juhlin, Claes et al.

Part of Clinical Positron Imaging, p. 339, 1999

• DOI for PET with [¹¹C]-Metomidate for the Visualization of Adrenocortical Tumors and Discrimination from Other Lesions

Positron emission tomography in neuroendocrine tumours

Eriksson, Barbro; Örlefors, Håkan; Sundin, Anders; Skogseid, Britt et al.

Part of The Italian Journal of Gastroenterology and Hepatology, 1999

Plasma Chromogranin A In Patients with Multiple Endocrine Neoplasia Type 1

Granberg, Dan; Stridsberg, Mats; Seensalu, Rein; Eriksson, Barbro et al.

Part of Journal of Clinical Endocrinology and Metabolism, p. 2712-2717, 1999

Whole-Body PET with [11C]-5-Hydroxytryptophan for Localization of Neuroendocrine Tumors.

Sundin, A; Sörrensen, J; Örlefors, H; Eriksson, B et al.

Part of Clin Positron Imaging, p. 338, 1999

Limited tumor involvement found at multiple endocrine neoplasia type I pancreatic exploration: can it be predicted by preoperative tumor localization?

Skogseid, Britt; Öberg, Kjell; Åkerström, Göran; Eriksson, Barbro et al.

Part of World Journal of Surgery, p. 673-677; discussion 667-668, 1998

• DOI for Limited tumor involvement found at multiple endocrine neoplasia type I pancreatic exploration: can it be predicted by preoperative tumor localization?

Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center

Tiensuu Janson, Eva; Holmberg, Lars; Stridsberg, Mats; Eriksson, Barbro et al.

Part of Annals of Oncology, p. 685-690, 1997

• DOI for Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center

Induction of apoptosis in neuroendocrine tumors of digestive system during treatment with somatostatin analogs.

Imam, Hassan; Eriksson, Barbro; Lukinius, Agneta; Tiensuu Janson, Eva et al.

Part of Acta Oncol., p. 60714, 1997

Tumour-induced hypoglycaemia in a patient with insulin-dependent diabetes mellitus

Svartberg, J; Stridsberg, Mats; Wilander, Erik; Andersson, D et al.

Part of Journal of Internal Medicine, p. 181-185, 1996

• DOI for Tumour-induced hypoglycaemia in a patient with insulin-dependent diabetes mellitus

The use of new somatostatin analogues, lanreotide and octastatin, inneuroendocrine gastro-intestinal tumours.

Eriksson, Barbro; Tiensuu Janson, E; Bax, ND; Mignon, M et al.

Part of Digestion, p. 77, 1996

Islet amyloid polypeptide (IAPP) in patients with neuroendocrine tumours

Stridsberg, Mats; Eriksson, Barbro; Lundqvist, Gudmar; Skogseid, Britt et al.

Part of Regulatory Peptides, p. 119-131, 1995

• DOI for Islet amyloid polypeptide (IAPP) in patients with neuroendocrine tumours

Islet amyloid polypeptide-producing pancreatic islet cell tumour: A clinical and biochemical characterization

Stridsberg, M; Wilander, E; Öberg, K; Lundqvist, G et al.

Part of Scand. J. Gastroenterol, p. 155-159, 1992

[New medical therapy of neuroendocrine gastrointestinal tumors]

Eriksson, B; Janson, E T; Skogseid, B; Oberg, K

Part of Lakartidningen, p. 2668-72, 1990

Interferon-induced enhancement of 2',5'-oligoadenylate synthetase in mid-gut carcinoid tumours.

Grander, D; Oberg, K; Lundqvist, M L; Tiensuu Janson, E et al.

Part of Lancet, p. 337-40, 1990

Systemic treatment of neuroendocrine tumors with hepatic metastases

Demırkan, Binnaz H M; Eriksson, Barbro

Part of Turkish Journal of Gastroenterology, p. 427-437, 2012

• DOI for Systemic treatment of neuroendocrine tumors with hepatic metastases

New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?

Eriksson, Barbro

Part of Current Opinion in Oncology, p. 381-386, 2010

• DOI for New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?

Medical management of islet cell carcinoma: Current Clinical Oncology

Eriksson, Barbro

Part of Neuroendocrine Tumors, p. 137-156, Springer Publishing Company, 2011

Medical management of islet cell carcinoma

Eriksson, Barbro

Part of Neuroendocrine Tumors, p. 137-156, Springer Science+Business Media B.V., 2011

Future treatment prospects

Eriksson, Barbro; Kulke, M

Part of Handbook of gastro enteroancreatic and thoracic neuroendocrine tumors, 2010

Carcinoid Syndrome

Öberg, Kjell; Eriksson, Barbro

Part of Endocrinology, Elsevier, 2005

PET for clinical diagnosis and research in neuroendocrine tumors

Eriksson, Barbro; Bergström, M; Örlefors, Håkan; Sundin, Anders et al.

Part of Diagn Nuclear Medicine 4th edition, p. 747-754, 2003

Neuroendocrine tumors: New perspection in their therapy

Eriksson, Barbro; Öberg, Kjell

Part of Advances in pancreatic disease, p. 376-96, Georg Thieme Verlag Stuttgart, New York, 2000

Neuroendocrine tumours

Öberg, Kjell; Eriksson, Barbro

Elsevier, 2007